BioWorld Asia

May 5, 2004

Peptech, Agenix Merging In Effort To Create Australian Powerhouse

SYDNEY, Australia - Two biotech companies agreed to a share-swap merger in what they declare is the first move in building Australia's biggest pure biotech company, with more acquisitions to come. (BioWorld International) Read More

Serono Secures Rights To 4SC Program In Autoimmune Disease

Work On Telomere Mechanism Opens New Avenues Of Research

NicOx, Ferrer Enter Collaboration To Develop Dermatology Drugs

Genmab Moving HuMax-CD4 Into Pivotal Program In CTCL

Swedish Biotech Group Decries State Of The Industry In Country

Aptanomics, Nanosyn Enter Deal To Discover Drugs For Cancer

Pharming Moves rhC1INH Into Pivotal Study In Angioedema

Prana Draws $20M Investment Following Trial In Alzheimer's

Innogenetics, Third Wave Enter Distribution Pact For Europe

Scancell Gains Interim Funding For ImmunoBody Technology

Glycoform Secures Funding For Work In Carbohydrate Delivery

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...